Prior Mycobacterium bovis BCG vaccination resulted in increased resistance as well as enhanced tuberculin hypersensitivity to both PPD-S (Mycobacterium tuberculosis) and PPD-A (M. avium). Mice heavily infected with M. avium were used as T-cell donors in an adoptive transfer system. Substantial resistance was observed for both recipient hosts regardless of the genotype of the donor strain. Transfer of resistance was ablated by treatment of the immune spleen cells with anti-Thy 1.2 monoclonal antibody and complement or by cyclophosphamide treatment. Spleen cells which were monodepleted of L3T4+ or Lyt-2+ T cells did not lose their ability to transfer resistance against a subsequent challenge. However, when these cells were doubly deleted, all resistance was ablated in both the BCG-susceptible and -resistant mice. The recipient host expressed a detectable adoptive immune response although the donor had been unable to reduce the growth of the primary M. avium infection in vivo.
The Mycobacterium avium complex (MAC) consists of a number of opportunistic pathogens which cause systemic disease only when the normal T-cell defenses have been depleted for some reason (20) . Patients with AIDS may develop disseminated M. avium disease which can reduce their mean survival time compared with that of MAC-free AIDS patients (10) . At present, we know very little about the role played by T cells in preventing the growth of M. avium in the tissues of the normal immunocompetent host (17) . While T-cell depletion will enhance the severity of some MAC infections, it does not affect others (8) , and we do not know whether T cells are directly involved in the expression of this innate resistance (2) .
Inbred mice can be distinguished on the basis of the presence of the Bcg' gene (9, 15) , which somehow limits the growth of M. avium within the lungs and spleens of intravenously infected mice (18) . When C57BL/6 (Bcgs) mice are infected with virulent M. avium, the infection continues within the lungs until all of the animals are dead, whereas the growth of the same organism in the resistant strain is quickly stabilized. The present study examines the nature of this striking difference in terms of the immune T-cell response seen within the infected spleens of the two groups of mice.
MATERIALS AND METHODS
Animals. Specific pathogen-free C57BL/6 (Bcgs) and (C57BL/6 x DBA/2)F1 (B6D2) hybrid (Bcg') mice were obtained from the Trudeau Animal Breeding Facility, Saranac Lake, N.Y. They were bred and maintained under barrier conditions and fed sterilized commercial mouse chow and acidified water ad libitum (8 avium was selected from a Middlebrook 7H11 agar plate, inoculated into Proskauer and Beck Tween liquid medium, and incubated at 37°C in roller bottles for 8 days before being stored at -70°C until required (7) . The viability of each suspension was checked 24 h after freezing by plating selected ampoules onto Middlebrook 7H11 agar (Difco, Detroit, Mich.). The plates were incubated at 37°C in sealed plastic bags for 3 weeks before the numbers of colonies were counted.
Animal inoculation. A frozen ampoule was thawed, sonicated briefly, and diluted in sterile saline so that 105 to 106 CFU was injected intravenously via a lateral tail vein. At weekly intervals, the numbers of viable organisms in the lungs and spleens were determined by homogenizing the organs separately in cold saline and plating them on 7H11 agar. In the case of BCG-vaccinated mice, the agar was enriched with 2-thiophene carboxylic acid hydrazide (2 jig/ml; Sigma Chemical Co., St. Louis, Mo.) to inhibit the growth of the residual BCG also present in the test organs (6). The limit of detection for viable mycobacteria was 50 CFU for the spleens and 100 CFU for the lungs. The counting error for five replicate mice was usually less than 10% of the mean.
Adoptive transfer studies using splenic T cells. Spleens were removed aseptically from the donor mice and pressed through a stainless steel screen into RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (GIBCO, Grand Island, N.Y.), 1 mM sodium pyruvate, 2 mM L-glutamine, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), and 5 x 10'5 M 2-mercaptoethanol but no antibiotics. The resulting cell suspension was enriched for T cells by a double-adherence protocol. The suspension was incubated in 5% C02-enriched air in tissue culture dishes (150 by 25 mm) which had been precoated with anti-macrophage monoclonal antibodies (F4/80 and Mac-1) for 45 min at 37°C. The nonadherent cells were removed by gently rinsing them with fresh medium and then incubating them for 30 min on plates precoated with goat anti-mouse immunoglobulin G (Cappel Labs, Cochranville, Penn.). The nonadherent cells were gently rinsed off and washed, and the number of viable cells was determined by dye exclusion
before the cells were standardized to a concentration of 2 x 107 cells per ml (12) .
The T-cell-enriched suspension was infused intravenously into sublethally irradiated (500 rad) syngeneic recipients at a one-spleen equivalency (13) . In some experiments, the donor mice were pretreated with 500 pug of anti-L3T4 (GK 1 (5) . The culture was incubated at 37°C in roller bottles for 8 to 10 days before the cells were removed by centrifugation at 10,000 x g for 20 min. The bacterial pellet was resuspended in PBS (pH 7.4) and heat killed at 56°C for 30 min. The suspension was checked for sterility and stored at -20°C until required. The cell suspension was subjected to sonic disruption at 0°C with a BraunSonic probe as described previously (19). The residual whole cells were removed by centrifugation at 10,000 x g at 4°C for 20 min followed by ultracentrifugation at 100,000 x g for 2 h. The clear supernatant fluid was sterilized by passage through a 0.45-,um-pore-size membrane filter. The protein content of the M. avium sonic extract (MASE) was determined with the bicinchoninic acid assay (Pierce, Rockford, Ill.) and a bovine serum albumin standard. The MASE was stored at -20°C until required.
Delayed-hypersensitivity determinations. Groups of infected mice were injected in the left hind footpad with 10 ,ug of purified protein derivative (Evans Medical, Langhurst, United Kingdom) or 10 jig of MASE dissolved in 25 ,ll of pyrogen-free saline (19). Saline was injected into the contralateral footpad, and the increase in foot thickness was compared by using dial gauge calipers at 3, 24, and 48 h. An increase of 0.18 mm (1.8 U) or more was considered to be significant at the 1% level (6) .
Statistical analysis. Viability data were analyzed by means of the Student t test or by an analysis of variance for differences between two or several independent means by using a Statview 512+ program (Brainpower, Calabases, Calif.) run on a Macintosh SE computer.
RESULTS
BCG vaccination and M. avium challenge. Groups of normal C57BL/6 and B6D2 mice were infected intravenously with the mouse-virulent strain M. avium 724, and the growth shown in Fig. 1 was observed over the following 12 weeks. The systemic infection in the Bcgs (C57BL/6) mice increased rapidly to reach lethal proportions after 10 to 12 weeks (individual mice showed counts of more than 1011 CFU per organ at this time). The increase in the M. avium spleen counts in the C57BL/6 mice was more than 10,000-fold over this 8-week period, compared with an increase of less than 20-fold in the resistant B6D2 mice. By 12 weeks, there was virtually no change in the M. avium counts in the Bcgr mice compared with that of the initial inoculum (Fig. 1) . No immune decline analogous to that observed with the spleens z _m.aVIUMI IL ¶ 1.1. To examine this phenomenon further, groups of C57BL/6 and B6D2 mice were first vaccinated subcutaneously in the nape of the neck region with 2 x 107 CFU of BCG Pasteur. The number of viable mycobacteria recovered from the spleen 3 weeks later was around 104 CFU. There was no obvious difference in the amount of growth by BCG Pasteur in the two mouse strains, a finding which seems compatible with earlier data (14) . Both groups of mice developed tuberculin hypersensitivity (Table 1) , which was enhanced by the M. avium challenge. Despite evidence for a cellular response by both groups of BCG-vaccinated mice, little difference was seen in the growth behavior of the M. avium challenge in the B6D2 (Bcg') mice. On the other hand, the M. avium counts for both the lungs and spleens in the BCG-vaccinated C57BL/6 mice did show some reduction in viability (P < 0.05) when examined at 4 weeks compared with that of the unvaccinated controls (Fig. 2) . This degree of reduction was in no way comparable to that seen in BCG-vaccinated mice challenged with virulent M. tuberculosis (Fig. 3) . BCG vaccination also resulted in an enhanced tuberculin hypersensitivity in the M. tuberculosis-challenged mice, whereas the unvaccinated controls quickly became anergic as the virulent infection developed (Table 1) .
Adoptive transfer of M. avium immunity by means of sensitized splenic T cells. The growth curves shown in Fig. 1 would suggest that the M. avium inoculum induced little or no cellular response, at least compared with that observed with the M. tuberculosis-infected mice (Fig. 3) . Adoptive transfer studies were carried out with splenic T cells harvested from 3-month-M. avium-infected C57BL/6 and B6D2 mice. The recipients were challenged 24 h later with 105 CFU of M. avium, and the numbers of viable mycobacteria in the lungs and spleens were determined at intervals. Mice infused with T cells harvested from the M. avium-infected C57BL/6 mice contained substantially fewer viable mycobacteria, both in the spleens (P = 0.05) and the lungs (P < 0.01), 1 month postchallenge than did the control mice, which received normal T cells (Fig. 4) . On the other hand, the recipients of the B6D2 T cells showed little evidence of any increase in resistance, although a reduction in the lung counts was seen 2 months after the onset of infection. None of the immune T-cell recipients exhibited a significant increase in the amount of footpad swelling following tuberculin testing.
Effect of T-cell depletion on the transfer of resistance. When immune spleen cells were depleted of L3T4+ or Lyt-2+ T cells 24 h prior to infusion into sublethally irradiated syngeneic recipients, growth of the M. avium challenge was largely unaffected compared with what was seen with the untreated controls. However, mice receiving doubly depleted (L3T4-and Lyt-2-) T cells failed to restrict the growth of the M. avium challenge in either lungs or spleens, the response resembling that seen in recipients of anti-Thy 1.2 antibody-treated cells. When the donor mice were pretreated with cyclophosphamide 24 h prior to transfer, the growth of the challenge inoculum actually increased somewhat compared with that seen with the controls (Fig. 4 ). 
DISCUSSION
The present study was undertaken to determine the nature of the immune response to a virulent M. avium infection in innately susceptible C57BL/6 mice compared with that in B6D2 (Bcg) mice. There was a substantial resistance to growth of the challenge organism within the spleens and somewhat less in the lungs (Fig. 2) . Prior BCG vaccination showed some protective value in the C57BL/6 (Bcgs) mice but none in the innately resistant B6D2 mice. This finding appears to be consistent with BCG protection data for children in Sweden, who showed an increased incidence of nontuberculous mycobacterial disease after BCG vaccination of newborns was terminated in 1975 (16) . This residual immunity in the adult population may be responsible for the lower incidence of MAC infections reported for AIDS patients in Scandinavia (10%) than in the United States (15 to 20%), where BCG vaccination has not been widely practiced (1, 10, 11) .
Despite the lack of any decline in the viability of the M. avium population within the spleens of the chronically infected C57BL/6 mice, spleen cells transferred substantial adoptive immunity to naive susceptible and resistant recipients (Fig. 4) response can be inferred from the ablation of this response when the T cells were treated with anti-Thy 1.2 monoclonal antibody and complement. The sensitivity of this transfer to cyclophosphamide treatment of the donor further suggests that these T cells are part of the memory-immune T-cell population in the chronically infected donor (13) . Cyclophosphamide treatment actually promoted the growth of the M. avium challenge in the recipient host, a phenomenon which clearly deserves further study.
Finally, it should be noted that depletion of the L3T4+ or Lyt-2+ T-cell subpopulation did not greatly ablate the expression of the immunity in the recipient. Depletion of both subsets was required to completely ablate the immune response, similar to what was seen with mice receiving anti-Thy 1.2-treated spleen cells (Fig. 4) . However, in each case, the response seen with the B6D2 recipient was less than that seen with the innately susceptible C57BL/6 mice.
